GU Cancers 2023 | Enfortumab vedotin and pembrolizumab vs platinum-based combination therapies for patients with mUC

Matthew R. Zibelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the efficacy that enfortumab vedotin and pembrolizumab have shown in the first-line setting for patients with metastatic urothelial carcinoma (mUC) and talks on the need to compare these treatments to platinum-based combination therapies for these patients. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.